NAS:CTNM (USA)
Â
Class A Common Stock
$
17.54
+1.61 (+9.87%)
10:08 PM EST
Warning! GuruFocus detected
1 Severe warning sign
with CTNM.
Try a 7-Day Free Trial
to check it out.
Current and historical daily PE Ratio for CTNM (
Contineum Therapeutics Inc
) from 2024 to Jun 11 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Contineum Therapeutics stock (CTNM) PE ratio as of Jun 11 2024 is 0.
More Details
Contineum Therapeutics Inc (CTNM) PE Ratio (TTM) Chart
Contineum Therapeutics Inc (CTNM) PE Ratio (TTM) Historical Data
View and export this data going back to 2024. Start your Free Trial
Total 47
- 1
| Contineum Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-11 | At Loss | 2024-05-08 | At Loss |
| 2024-06-10 | At Loss | 2024-05-07 | At Loss |
| 2024-06-07 | At Loss | 2024-05-06 | At Loss |
| 2024-06-06 | At Loss | 2024-05-03 | At Loss |
| 2024-06-05 | At Loss | 2024-05-02 | At Loss |
| 2024-06-04 | At Loss | 2024-05-01 | At Loss |
| 2024-06-03 | At Loss | 2024-04-30 | At Loss |
| 2024-05-31 | At Loss | 2024-04-29 | At Loss |
| 2024-05-30 | At Loss | 2024-04-26 | At Loss |
| 2024-05-29 | At Loss | 2024-04-25 | At Loss |
| 2024-05-28 | At Loss | 2024-04-24 | At Loss |
| 2024-05-24 | At Loss | 2024-04-23 | At Loss |
| 2024-05-23 | At Loss | 2024-04-22 | At Loss |
| 2024-05-22 | At Loss | 2024-04-19 | At Loss |
| 2024-05-21 | At Loss | 2024-04-18 | At Loss |
| 2024-05-20 | At Loss | 2024-04-17 | At Loss |
| 2024-05-17 | At Loss | 2024-04-16 | At Loss |
| 2024-05-16 | At Loss | 2024-04-15 | At Loss |
| 2024-05-15 | At Loss | 2024-04-12 | At Loss |
| 2024-05-14 | At Loss | 2024-04-11 | At Loss |
| 2024-05-13 | At Loss | 2024-04-10 | At Loss |
| 2024-05-10 | At Loss | 2024-04-09 | At Loss |
| 2024-05-09 | At Loss | 2024-04-08 | At Loss |
Contineum Therapeutics Inc (CTNM) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Contineum Therapeutics Inc
NAICS : 541713
SIC : 2833
Share Class Description:
CTNM: Class A Common StockDescription
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers